Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 4:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Oral Ulcers Clear all
Completed Not applicable Interventional Results available

Impact of Omega-3 Fatty Acid Oral Therapy on Healing of Chronic Venous Leg Ulcers in Older Adults

NCT03576989
View directory record Official record
Conditions
Chronic Venous Leg Ulcers
Interventions
EPA+DHA, placebo
Dietary Supplement · Other
Lead sponsor
Ohio State University
Other
Eligibility
55 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 24, 2026, 4:01 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative Colitis

NCT02895100
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
PTG-100, Placebo
Drug
Lead sponsor
Protagonist Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
21
States / cities
Los Angeles, California • Colorado Springs, Colorado • Miami, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Sep 24, 2026, 4:01 PM EDT
Completed Phase 2 Interventional Results available

Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis

NCT05570006
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
ABBV-668
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
18
States / cities
Chula Vista, California • Maitland, Florida • Margate, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 24, 2026, 4:01 PM EDT
Recruiting Phase 4 Interventional

Effects of Photobiomodulation (PBM) on Pain After Presentation of Aphthous Ulcers in Pediatric Dental Patients

NCT06819033
View directory record Official record
Conditions
Aphthous Ulcer
Interventions
PBM Therapy, Maalox plus Benadryl
Device · Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
5 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Sep 24, 2026, 4:01 PM EDT
Terminated Early Phase 1 Interventional

Refined Fecal Microbiota Transplantation (FMT) for Ulcerative Colitis (UC)

NCT04968951
View directory record Official record
Conditions
Ulcerative Colitis, FMT, Fecal Microbiota Transplant
Interventions
Metronidazole, Placebo, Vancomycin, Fecal Microbiota Transplantation
Drug · Biological
Lead sponsor
Ari M Grinspan
Other
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 25, 2024 · Synced Sep 24, 2026, 4:01 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis

NCT02435992
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
RPC1063, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,012 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
113
States / cities
Sun City, Arizona • Tucson, Arizona • North Little Rock, Arkansas + 87 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2021 · Synced Sep 24, 2026, 4:01 PM EDT
Completed Phase 2 Interventional

Miracle Mouthwash Plus Hydrocortisone vs Prednisolone Mouth Rinse for Mouth Sores Caused by Everolimus

NCT02229136
View directory record Official record
Conditions
Stomatitis, Oral Mucositis, Neoplasm of the Breast, Malignant Tumor of Breast
Interventions
Miracle Mouthwash Plus Hydrocortisone, Prednisolone
Drug
Lead sponsor
US Oncology Research
Industry
Eligibility
18 Years and older · Female only
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
US, Texas
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Sep 24, 2026, 4:01 PM EDT
Active, not recruiting Phase 3 Interventional

Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.

NCT05782907
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 17 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
20
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Corona, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 24, 2026, 4:01 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

NCT04254783
View directory record Official record
Conditions
Ulcerative Colitis (UC), Crohn's Disease
Interventions
Risankizumab, Cytochrome P450 (CYP) Substrates
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
Coronado, California • DeLand, Florida • Margate, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2024 · Synced Sep 24, 2026, 4:01 PM EDT
Completed Phase 2 Interventional

PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC)

NCT04504383
View directory record Official record
Conditions
Ulcerative Colitis Chronic Moderate, Ulcerative Colitis Chronic Severe
Interventions
PN-943, Placebo
Drug
Lead sponsor
Protagonist Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
31
States / cities
Tucson, Arizona • Garden Grove, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Sep 24, 2026, 4:01 PM EDT
Completed No phase listed Observational

AONDA Therapeutic Indication Study I

NCT05891106
View directory record Official record
Conditions
Bullous Keratopathy, Corneal Erosion, Entropion, Corneal Edema, Corneal Dystrophy, Corneal Ulcer, Foreign Body in Cornea, Bell Palsy, Keratoconjunctivitis, Filamentary Keratitis, Sicca Syndrome; Keratoconjunctivitis (Etiology)
Interventions
Lotrafilcon A contact lenses
Device
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
3
States / cities
Orlando, Florida • Franklin Park, Illinois • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Sep 24, 2026, 4:01 PM EDT
Completed Phase 3 Interventional Results available

Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)

NCT01532648
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Budesonide MMX®, Placebo, 5-ASA
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
39
States / cities
Anaheim, California • Lakewood, California • San Diego, California + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2019 · Synced Sep 24, 2026, 4:01 PM EDT
Not listed Phase 2 Interventional

Topical Pentoxifylline Gel on Behcet's Disease Genital Ulcers

NCT04186559
View directory record Official record
Conditions
Behcet Syndrome, Behcet Disease
Interventions
Topical Pentoxifylline Gel (Vehicle +PTX), Topical Placebo Gel (Vehicle)
Drug
Lead sponsor
Silk Road Therapies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Sep 24, 2026, 4:01 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis

NCT01582880
View directory record Official record
Conditions
Chemical Injuries, Unspecified Complication of Corneal Transplant, Autoimmune Diseases, Ocular Cicatricial Pemphigoid, Stevens Johnson Syndrome, Lupus Erythematosus, Systemic, Rheumatoid Arthritis, Other Autoimmune Diseases
Interventions
Riboflavin
Drug
Lead sponsor
Joseph B. Ciolino, MD
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 20, 2019 · Synced Sep 24, 2026, 4:01 PM EDT
Completed Phase 3 Interventional Results available

A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis

NCT01458574
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Placebo, CP690,550, CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
593 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
94
States / cities
Mobile, Alabama • La Jolla, California • Oceanside, California + 47 more
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Sep 24, 2026, 4:01 PM EDT
Completed Not applicable Interventional

Trial of Oral Versus Intravenous Proton Pump Inhibitor on Intragastric pH in Patients With Bleeding Ulcers

NCT00573924
View directory record Official record
Conditions
Peptic Ulcer Hemorrhage
Interventions
Proton pump inhibitor (lansoprazole)
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2011 · Synced Sep 24, 2026, 4:01 PM EDT
Terminated Phase 1 Interventional

A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative Colitis

NCT05549323
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
PF-07054894, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
7
States / cities
Kissimmee, Florida • Tampa, Florida • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 24, 2026, 4:01 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

NCT05635266
View directory record Official record
Conditions
Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
Interventions
Specimen sample
Diagnostic Test
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Sep 24, 2026, 4:01 PM EDT
Active, not recruiting Phase 2 Interventional

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

NCT06254950
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
TAK-279, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
16
States / cities
Los Angeles, California • Murrieta, California • Clearwater, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 24, 2026, 4:01 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of RK0202 in Oral Mucositis

NCT00230191
View directory record Official record
Conditions
Mouth Diseases, Mouth Ulcers, Oral Mucositis, Head and Neck Cancer
Interventions
RK-0202
Drug
Lead sponsor
RxKinetix
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
6
States / cities
Los Angeles, California • Tampa, Florida • Louisville, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2007 · Synced Sep 24, 2026, 4:01 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis

NCT05785715
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
NX-13 250mg, NX-13 750mg, NX-13 Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
11
States / cities
Miami, Florida • Orlando, Florida • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 24, 2026, 4:01 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Luminance RED for Canker Sores

NCT04914533
View directory record Official record
Conditions
Canker Sore
Interventions
Luminance RED Low Level Laser Therapy Device
Device
Lead sponsor
ProofPilot
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 24, 2026, 4:01 PM EDT
Terminated Phase 2 Interventional Results available

The Use of Oral Budesonide and Rectal Hydrocortisone for the Treatment of Active Ulcerative Colitis

NCT00805285
View directory record Official record
Conditions
Inflammatory Bowel Disease, Ulcerative Colitis
Interventions
Combination Oral Budesonide and Rectal Hydrocortisone
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Sep 24, 2026, 4:01 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Green Tea Extract (Polyphenon E®)in Ulcerative Colitis

NCT00718094
View directory record Official record
Conditions
Mild to Moderately Active Ulcerative Colitis
Interventions
Polyphenon E®, Placebo Oral Tablet
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Sep 24, 2026, 4:01 PM EDT